论文部分内容阅读
应用聚合酶链反应（PCR）技术制备非放射性探针标记物——地高辛素标记人类乳头瘤病毒（HPV）共有引物探针，对146例喉不同病变的新鲜组织标本（喉癌68例，喉其它病变48例，正常喉组织30例）进行HPV6，11，16，18，31，33，35，42，58共9型HPVSDNAS感染的检测。结果表明，喉癌组HPV感染阳性率45．6％（31／68），喉癌颈转移淋巴结组阳性率21．0％（3／15），喉癌前病变阳性率11．8％（2／17），声带息肉组阳性率6．3％（1／16），15例癌旁及15例癌周正常喉组织均为HPVDNA阴性。文中还对HPV在喉癌中的致病作用及应用PCR技术制备地高李标记HPV共有引物探针的敏感性及特异性进行了讨论。
Polymerase chain reaction (PCR) technology was used to prepare non-radioactive probe marker-digoxigenin-labeled human papillomavirus (HPV) common primer probe. 146 specimens of laryngeal carcinoma , 48 cases of other laryngeal lesions, and 30 cases of normal laryngeal tissues) were tested for HPV type 9, 9, 16, 18, 31, 33, 35, 42, The results showed that the positive rate of HPV infection in laryngeal cancer group was 45.6% (31/68), the positive rate of cervical lymph node metastasis in laryngeal cancer group was 21.0% (3/15), and the positive rate of laryngeal precancerous lesion group was 11.8% (2) / 17). The positive rate of vocal cord polyps was 6.3% (1/16). HPVDNA negative was found in 15 cases of pericancerous tissue and 15 cases of normal peritumoral laryngeal tissues. The paper also discussed the pathogenicity of HPV in laryngeal carcinoma and the sensitivity and specificity of PCR-based high-molecular-weight labeled HPV consensus primer probe.